GlassScriptPhysician profile
Catherine M Weber
NPI 1487315891
$4,958.44
in general payments reported to CMS, 2019-2025
46 companies · $3,469 in 2025
The $3,469 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,490 · 2025: $3,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,875 · Education: $83.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,874.64 |
| Education | $83.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $479.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $455.14 | 2024-2025 | Imfinzi, Enhertu, Calquence |
| Bayer Healthcare Pharmaceuticals INC. | $394.14 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $341.92 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $296.15 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $263.33 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $227.45 | 2024-2025 | |
| Daiichi Sankyo INC. | $217.56 | 2024-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $205.08 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $148.80 | 2024-2025 | Opdivo |
| Glaxosmithkline, LLC. | $147.91 | 2025 | Ojjaara, Zejula, Jemperli |
| Stemline Therapeutics INC. | $147.12 | 2025 | Orserdu |
| Lilly USA, LLC | $143.58 | 2024-2025 | Jaypirca, Verzenio |
| Geron Corporation | $124.96 | 2025 | Rytelo |
| Sobi, INC | $121.35 | 2024-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $113.27 | 2024-2025 | Carvykti |
| Beone Medicines USA, INC. | $89.26 | 2025 | Brukinsa |
| Array Biopharma INC | $78.27 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $66.33 | 2024-2025 | Cosela, Monoferric |
| Alexion Pharmaceuticals, INC. | $64.21 | 2024-2025 | Ultomiris |
| Celgene Corporation | $63.89 | 2024-2025 | Opdualag, Reblozyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.25 | 2025 | |
| Dendreon Pharmaceuticals LLC | $59.79 | 2025 | Provenge |
| Genmab U.S., INC. | $51.29 | 2024 | Epkinly |
| Agios Pharmaceuticals, INC. | $50.18 | 2024-2025 | Pyrukynd |
| Beigene USA, INC. | $49.87 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $49.31 | 2024-2025 | |
| Genentech USA, INC. | $46.52 | 2024 | Polivy, Tecentriq, Alecensa |
| Genzyme Corporation | $46.46 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $39.59 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $37.25 | 2025 | Lynozyfic |
| Jazz Pharmaceuticals INC. | $24.50 | 2025 | |
| Servier Pharmaceuticals LLC | $23.36 | 2025 | |
| Rigel Pharmaceuticals, INC. | $21.79 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Eisai INC. | $20.75 | 2025 | |
| Deciphera Pharmaceuticals INC. | $20.72 | 2025 | Tgct, Qinlock |
| Emd Serono, INC. | $19.57 | 2025 | |
| Adc Therapeutics America, INC. | $18.63 | 2024 | |
| Exelixis INC. | $18.41 | 2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $16.55 | 2025 | Orgovyx |
| Kite Pharma, INC. | $16.42 | 2025 | Yescarta |
| Astellas Pharma US INC | $15.95 | 2025 | Padcev |
| Recordati_rare_diseases_inc. | $15.91 | 2025 | Sylvant |
| Bioprotect Medical, INC. | $15.39 | 2025 | Bioprotect Balloon Implant System |
| Pharmaessentia USA Corporation | $14.40 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $13.46 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.